University of California

The Schepens Eye Research Institute, Inc.

Lubris LLC

Tearlab Research, Inc.

Ocusense, Inc.

Code Footwear, LLC

Other

Rhode Island Hospital

Benjamin D Sullivan

David A Sullivan

Tannin Avery Schmidt

Eric Donsky

Gregory D Jay

Michael J Heller

Tannin A Schmidt

Edward R Truitt, Iii

Geert W Schmid-Schoenbein

Roy B Lefkowitz

Nicole Justis Truitt

Matthew Daniel Solomon

Daniel Kincade

Jawed Fareed

Erol Craig Harvey

Edward R Truitt

Roman Krawetz

Khaled Elsaid

Zeyad Moussa

Steve Zmina

Tannin Schmidt

Nicole Barbara Truitt

Dennis A Carson

Sadik C Esener

Dietrich A Dehlinger

Rajaram Krishnan

Brandon Westerberg

Peter Van Ruijven

Matthew Springer

Fred Harry Davis

Adam Chodobski

Joanna Szmydynger-Chodobska

Carl Gang Chen

Graeme John Bullock

Nicole Barbara Justis Truitt

Melissa Lee

Christian Potzner

Sebastiaan Garst

Jason Hayes

Peter Munster

Michael Wilkinson

Joanna Slowinska

Derek Lee

Nicholas Tennison

Sasha Miu

Adam Ernest Donath

Andreas Knaack

Michael Heller

Dennis Carson

Sadik Esener

Edward R Iii Truitt

Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature. In these instances PRG4 glycoprotein adheres to extracellular matrix or cell surfaces and presents a glycol-surface of polysaccharide which blocks the mechanisms of cell motility, extravasation, or intravasation, inhibits sticking of macrophages and platelets, and/or serves as a substitute or mimic of native glycocalyx.

Compositions and methods for inhibiting intercellular interactions

Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-&#x3ba;B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Use of PRG4 as an anti-inflammatory agent

Disclosed are methods involving the therapeutic use of human PRG4 (lubricin) protein, to improve vision, to reduce aberrations such as impaired night vision, halos, and glare, to improve the stability of the tear film, and to homogenize the refractive index of the surface of the eye.

Use of PRG4 to improve dynamic visual acuity and higher order aberrations

Systems, methods, and devices for analyzing small volumes of fluidic samples, as a non-limiting example, less than twenty microliters are provided. The devices are configured to make a first sample reading, for example, measure an energy property of the fluid sample, for example, osmolality, make a second sample reading, for example, detecting the presence or concentration of one or more analytes in the fluid sample, or make both the first sample reading and the second sample reading, for example, measuring the energy property of the fluid sample as well as detecting the presence or concentration of one or more analytes in the fluid sample.

Systems and methods for integration of microfluidic tear collection and lateral flow analysis of analytes of interest

Provided herein is a pharmaceutical or oral care product for treating or preventing oral diseases that is prepared with proteoglycan 4 (PRG4) as an active ingredient, the preparing method thereof and the use thereof in manufacturing medicaments or oral care products for treating or preventing oral diseases and maintenance of oral health. PRG4 may have efficacy in maintaining oral health and treating or preventing oral disease. This secreted glycoprotein, which is also called lubricin and superficial zone protein, is known to protect against frictional forces, cell adhesion and protein deposition.

Oral care compositions and methods

Provided herein are methods for the modulation of appearance or material properties within items of apparel or equipment. Also provided herein are design articles having alterable designs.

Reconfigurable apparel manufacture and business process

Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature. In these instances PRG4 glycoprotein adheres to extracellular matrix or cell surfaces and presents a glycol-surface of polysaccharide which blocks the mechanisms of cell motility, extravasation, or intravazation, inhibits sticking of macrophages and platelets, and/or serves as a substitute or mimic of native glycocalyx.

Provided herein are methods for the modulation of appearance or material properties within items of apparel or equipment. Also provided herein are design articles having alterable designs. Generally, such design articles comprise (1) a microfluidic circuit, and (2) an inlet and an outlet, the alterable design capable of being modulated through use of a docking system to deliver fluid to the microfluidic circuit.

Reconfigurable shoes and apparel and docking assembly therefor

The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.

Application and uses of PRG4 and therapeutic modulation thereof

The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Compositions for treating dry eye disease

Provided herein are compositions useful in detecting degradative enzymes and biomolecules in bodily fluid samples.

Detection of degradative enzymes and biomolecules in bodily fluids

Reconfigurable apparel manufacture and business processes

Growing community of inventors

San Diego, CA, United States of America

Benjamin D Sullivan